Another First-Line Combo Succeeds in Advanced RCC

(MedPage Today) -- Advanced or metastatic kidney cancer patients treated with the PD-1 checkpoint inhibitor nivolumab (Opdivo) plus cabozantinib (Cabometyx) lived twice as long without disease progression compared to patients receiving an older...